Close
Solutions
Online Inquiry
Global Services

Anti-MAGEA4 CAR-T Preclinical In Vivo Assay

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Target Background

MAGEA4 (melanoma-associated antigen 4) is very similar to MAGEA3. It is expressed only in immune privileged reproductive tissues (primary spermatocytes, spermatogonia in male and placental trophoblast in female). As a tumor-specific protein, MAGEA4 also expresses exclusively and aberrantly on multiple tumors (melanoma, non-small cell lung cancer, hematologic malignancies, etc.) excluding most normal somatic cells, and plays an active role in driving cancer progression and indicates bad prognosis. Therefore, MAGEA4 is an attractive immunotherapeutic target for the anti-MAGEA4 CAR-T cell therapy.

Structures of MAGEA4

Structures of MAGEA4
Diagram created by Creative Biolabs based on data from PloS one 11.2 (2016): e0148762

Anti-MAGEA4 CAR-T Cell Therapy

Since MAGEA4 plays a critical role in multiple human malignancies, several phase 1 clinical trials (NCT02239861, NCT02291848, NCT01333046) try to apply tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes for the treatment of multiple human malignancies. Creative Biolabs is dedicated to assisting researchers to initiate and develop the cutting-edge anti-MAGEA4 CAR-T cell therapy.

Animal Models for in vivo Study of anti-MAGEA4 CAR-T Cell Therapy

Creative Biolabs offers researchers almost all the animal models generated from the major techniques including the conventional carcinogen-induced models, the mosaic transposon- or virus-induced models, the transgenic models and the subcutaneous or patient-derived xenograft models for a variety of human malignancies. In addition, Creative Biolabs also assists customers in creating clinically relevant animal models including but not limited to the above categories. You request, Creative Biolabs offers the best.

In vivo Assay Parameters and Techniques

At Creative Biolabs, we offer the most exquisite and comprehensive service platform for preclinical MAGEA4 CAT-T cell therapy research.
Efficacy Test
Tumor remission monitored by tumor volume recording or bioluminescence imaging and survival curve tracking
Viability and Bio-distribution Studies
Durability, GLP-compliant bio-distribution studies
Toxicity Evaluation
Pilot tolerability (MTD, The route of administration, Dose regimen/response/onset)
Clinical observation (body weight, feed consumption, ophthalmologic and clinical pathology)
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
Complete necropsy, organ weight
Histopathology
Tumorigenicity study

Creative Biolabs outperforms the entire biotechnological community to back researchers with every resource for establishing the most reliable and subtle animal models in advance to help the customer achieve incredible disproportionate results and exponentially greater value. Creative Biolabs assists researchers in making the scientific history.

References

  1. Newman, Joseph A., et al. "Structures of two melanoma-associated antigens suggest allosteric regulation of effector binding." PloS one 11.2 (2016): e0148762.
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.